by Jason Heaviland | Jun 15, 2026
This data report presents the complete Cell Surface Multi-Omics analysis of KRAS-knockdown and wild-type HCT-116 cells, including cell surface proteomics, membrane lipidomics, differential expression analysis and integrated protein–lipid interpretation from matched...
by Jason Heaviland | Jun 15, 2026
KRAS Knockdown Remodels Surface Proteins and Lipids Cell Surface Multi-Omics combines cell surface proteomics and membrane lipidomics from matched membrane fractions to characterize the protein and lipid architecture of the cell surface. In KRAS-knockdown HCT-116...
by Jason Heaviland | Jun 15, 2026 | Uncategorized
Why Cell Therapy Target Selection Is So Difficult Antibody-drug conjugates (ADCs) and CAR-T therapies have reshaped modern oncology, but their success still depends on one deceptively simple question: are we targeting the right protein? In practice, answering this is...
by Jason Heaviland | May 21, 2026 | Uncategorized
Drug development is expensive, slow, and highly unpredictable. Despite major advances in genomics and precision medicine, nearly 90% of drug candidates still fail (Doi: 10.1016/j.apsb.2022.02.002) during clinical development, often because the selected target was not...
by ODWAdmin | Sep 25, 2025 | Uncategorized
Antibody-drug conjugates (ADCs) represent a paradigm shift in targeted cancer therapy, combining the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs through sophisticated linker chemistry. Despite remarkable clinical successes...
